An antibiotic decision-making tool for patients with pneumonia admitted to a medical intensive care unit

International Journal of Antimicrobial Agents

Volumn 48, Issue 3, 2016, Pages 286-291

  Huang, Sheng Feng ^a   Chang, Jung San ^b,c   Sheu, Chau Chyun ^b,c   Liu, Yu Ting ^a   Lin, Ying Chi ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Antibiotic; Critical care; Decision making; Intensive care unit; Multidrug resistant; Pneumonia

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; MACROLIDE; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; TIGECYCLINE; ANTIINFECTIVE AGENT;

ACCURACY; ACHROMOBACTER XYLOSOXIDANS; ACINETOBACTER BAUMANNII; ADULT; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL VENTILATION; COHORT ANALYSIS; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; HEALTH CARE FACILITY; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; AGED; DECISION SUPPORT SYSTEM; EVALUATION STUDY; FEMALE; MALE; MICROBIOLOGY; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DECISION SUPPORT TECHNIQUES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PNEUMONIA; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84984860952     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.05.013     Document Type: Article

References (30)

1. [1] De Pascale, G., Bello, G., Tumbarello, M., Antonelli, M., Severe pneumonia in intensive care: cause, diagnosis, treatment and management: a review of the literature. Curr Opin Pulm Med 18 (2012), 213–221.
2. [2] Iregui, M., Ward, S., Sherman, G., Fraser, V.J., Kollef, M.H., Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122 (2002), 262–268.
3. [3] Rosón, B., Carratalà, J., Fernández-Sabé, N., Tubau, F., Manresa, F., Gudiol, F., Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 164 (2004), 502–508.
4. [4] Bassetti, M., De Waele, J.J., Eggimann, P., Garnacho-Montero, J., Kahlmeter, G., Menichetti, F., et al. Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med 41 (2015), 776–795.
5. [5] Kollef, M.H., Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 31:Suppl. 4 (2000), S131–8.
6. [6] Martin-Loeches, I., Torres, A., Rinaudo, M., Terraneo, S., de Rosa, F., Ramirez, P., et al. Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms. J Infect 70 (2015), 213–222.
7. [7] Guillamet, C.V., Kollef, M.H., ‘Does this patient have…’ ‘Is this patient at risk for infection with multidrug resistant bacteria?’. Intensive Care Med, 2015, 10.1007/s00134-015-4126-1 Epub ahead of print.
8. [8] American Thoracic Society, Infectious Diseases Society of America, Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005), 388–416.
9. [9] Mandell, L.A., Wunderink, R.G., Anzueto, A., Bartlett, J.G., Campbell, G.D., Dean, N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44:Suppl. 2 (2007), S27–72.
10. [10] Ewig, S., Welte, T., Chastre, J., Torres, A., Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis 10 (2010), 279–287.
11. [11] Xie, J., Ma, X., Huang, Y., Mo, M., Guo, F., Yang, Y., et al. Value of American Thoracic Society guidelines in predicting infection or colonization with multidrug-resistant organisms in critically ill patients. PLoS ONE, 9, 2014 e89687.
12. [12] Aliberti, S., Cilloniz, C., Chalmers, J.D., Zanaboni, A.M., Cosentini, R., Tarsia, P., et al. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective. Thorax 68 (2013), 997–999.
13. [13] Aliberti, S., Di Pasquale, M., Zanaboni, A.M., Cosentini, R., Brambilla, A.M., Seghezzi, S., et al. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis 54 (2012), 470–478.
14. [14] Park, S.C., Kang, Y.A., Park, B.H., Kim, E.Y., Park, M.S., Kim, Y.S., et al. Poor prediction of potentially drug-resistant pathogens using current criteria of health care-associated pneumonia. Respir Med 106 (2012), 1311–1319.
15. [15] Park, S.C., Kim, E.Y., Kang, Y.A., Park, M.S., Kim, Y.S., Kim, S.K., et al. Validation of a scoring tool to predict drug-resistant pathogens in hospitalised pneumonia patients. Int J Tuberc Lung Dis 17 (2013), 704–709.
16. [16] Shindo, Y., Ito, R., Kobayashi, D., Ando, M., Ichikawa, M., Shiraki, A., et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med 188 (2013), 985–995.
17. [17] Shorr, A.F., Zilberberg, M.D., Micek, S.T., Kollef, M.H., Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. Arch Intern Med 168 (2008), 2205–2210.
18. [18] Shorr, A.F., Zilberberg, M.D., Reichley, R., Kan, J., Hoban, A., Hoffman, J., et al. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis 54 (2012), 193–198.
19. [19] Schreiber, M.P., Chan, C.M., Shorr, A.F., Resistant pathogens in nonnosocomial pneumonia and respiratory failure: is it time to refine the definition of health-care-associated pneumonia?. Chest 137 (2010), 1283–1288.
20. [20] Laupacis, A., Sekar, N., Stiell, I.G., Clinical prediction rules. A review and suggested modifications of methodological standards. JAMA 277 (1997), 488–494.
21. [21] Wasson, J.H., Sox, H.C., Neff, R.K., Goldman, L., Clinical prediction rules. Applications and methodological standards. N Engl J Med 313 (1985), 793–799.
22. [22] Gross, A.E., Van Schooneveld, T.C., Olsen, K.M., Rupp, M.E., Bui, T.H., Forsung, E., et al. Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia. Antimicrob Agents Chemother 58 (2014), 5262–5268.
23. [23] Wu, C.L., Ku, S.C., Yang, K.Y., Fang, W.F., Tu, C.Y., Chen, C.W., et al. Antimicrobial drug-resistant microbes associated with hospitalized community-acquired and healthcare-associated pneumonia: a multi-center study in Taiwan. J Formos Med Assoc 112 (2013), 31–40.
24. [24] Sellars, C., Bowie, L., Bagg, J., Sweeney, M.P., Miller, H., Tilston, J., et al. Risk factors for chest infection in acute stroke: a prospective cohort study. Stroke 38 (2007), 2284–2291.
25. [25] Armstrong, J.R., Mosher, B.D., Aspiration pneumonia after stroke: intervention and prevention. Neurohospitalist 1 (2011), 85–93.
26. [26] Cassir, N., Papazian, L., Fournier, P.E., Raoult, D., La Scola, B., Insights into bacterial colonization of intensive care patients' skin: the effect of chlorhexidine daily bathing. Eur J Clin Microbiol Infect Dis 34 (2015), 999–1004.
27. [27] Hu, H.C., Huang, C.C., Tsai, Y.H., Lee, C.H., Hsieh, M.J., Outcome analysis of patients requiring mechanical ventilation with severe community-acquired pneumonia and identified bacterial pathogens. Chang Gung Med J 28 (2005), 229–236.
28. [28] Kang, C.I., Kim, S.H., Park, W.B., Lee, K.D., Kim, H.B., Kim, E.C., et al. Bloodstream infections caused by antibiotic-resistant Gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 49 (2005), 760–766.
29. [29] Restrepo, M.I., Peterson, J., Fernandez, J.F., Qin, Z., Fisher, A.C., Nicholson, S.C., Comparison of the bacterial etiology of early-onset and late-onset ventilator-associated pneumonia in subjects enrolled in 2 large clinical studies. Respir Care 58 (2013), 1220–1225.
30. [30] Scholte, J.B., Duong, H.L., Linssen, C., Van Dessel, H., Bergmans, D., van der Horst, R., et al. Empirical antibiotic therapy for pneumonia in intensive care units: a multicentre, retrospective analysis of potentially pathogenic microorganisms identified by endotracheal aspirates cultures. Eur J Clin Microbiol Infect Dis 34 (2015), 2295–2305.